A Phase I Study of Hetrombopag Olamine in Healthy Adult Volunteers

NCT ID: NCT01830660

Last Updated: 2015-04-06

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 96 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2012-04-30
• Study Completion Date: 2013-06-30

Brief Summary

Hetrombopag Olamine made by Jiangsu Hengrui Medicine co Ltd. has shown an effect of increasing platelet count in animal and human. This study is designed in dose escalation fashion to evaluate safety, pharmacokinetics and efficacy of Hetrombopag Olamine.

Detailed Description

1. To evaluate safety and tolerability of Hetrombopag Olamine.

2. To investigate pharmacokinetics of Hetrombopag Olamine Under fasting conditions.

3. To obtain pharmacodynamics information of Hetrombopag Olamine on platelet count elevation in healthy volunteers.

4. To determine preliminary regimen for phase II study.

Conditions

Healthy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

hetrombopag

hetrombopag either at 2.5,5,10,20,30 or 40mg, p.o. once daily

Group Type: EXPERIMENTAL

Hetrombopag Olamine Tablets

Intervention Type: DRUG

placebo

Subjects will be randomized (5:1 eltrombopag : placebo) to receive either eltrombopag or placebo.

Group Type: PLACEBO_COMPARATOR

placebo

Intervention Type: DRUG

Interventions

Hetrombopag Olamine Tablets

Intervention Type: DRUG

placebo

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Subject must be adequately informed of the nature and risks of the study, able to understand the risks associated with the study, and are willing to provide written informed consent prior to screening.

2. Must be a healthy male between the ages of 18 to 45 years, inclusive.

3. Must have a BMI between 19 to 28 kg/m2, inclusive and a total body weight ≥50 kg.

4. Platelet counts must be within the normal range.

5. Subjects must be free of any clinically significant disease based on medical history and physical examination.

6. Clinical laboratory tests (complete blood count [CBC], blood chemistries, and urinalysis) must be within the normal limits or clinically acceptable.

7. Must be nonsmokers, defined as not having smoked tobacco or used chewing tobacco or nicotine.

8. Subjects of reproductive potential with partners who are women of childbearing potential, will be instructed to, and must be willing to practice a highly effective method of birth control for the duration of the study and continuing 6 months after discontinuing treatment with the investigational product.

Exclusion Criteria

1. History of hypersensitivity to hetrombopag olamine or its components.

2. History or presence of significant cardiovascular deficient, pulmonary, hepatic, gallbladder or biliary tract, renal, hematological, gastrointestinal, endocrine, immunological, dermatological, neurological, or psychiatric disease, or any other condition known to interfere with the absorption, distribution, metabolism, or excretion of drugs.

3. History of deep vein thrombosis, or any other thromboembolic event.

4. History or presence of conditions that may place the subject at increased risk as determined by the investigator.

5. History of thrombocytopenia or bleeding due to abnormal platelet number or function.

6. History of platelet clumping that prevents reliable measurement of platelet counts.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 45 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: Yes

Sponsors

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Maozhi Liang, Dr

Role: PRINCIPAL_INVESTIGATOR

West China Hospital

Locations

West China Hospital, Sichuan University

Chengdu, Sichuan, China

Countries

China

Other Identifiers

SHR-TPOP1

Identifier Type: -

Identifier Source: org_study_id